| PolysacDB ID | 2383 |
| Carbohydrate Name | Surface Polysaccharide Poly-N-Acetylglucosamine [PNAG] (Drugpedia) |
| Carbohydrate Class | Capsular polysaccharide |
| Microbe | Staphylococcus aureus (NCBI Taxonomy) (Drugpedia) |
| Basic Structure | PNAG consists of a backbone of N-acetylglucosamine residues of variable lendth
|
| BCSDB Structure | 21574 |
| Proposed functions | PNAG also referred to as the polysaccharide intercellular adhesin, has been shown to elicit opsonic antibodies when used as a vaccine in goats and rabbits. In addition, these polyclonal antibodies passively protect mice against S. aureus bacteremia and renal infection as well as against lethality following a high-dose infection. Animal antibodies to PNAG also mediate killing of S. epidermidis strains that express this antigen, and these strains constitute a significant proportion of clinical isolates |
| Antigenic Nature used to produce antibodies | Staphylococcus aureus infected patients |
| Carrier Name | Nil |
| Conjugation Method | Nil |
| Antibodies | Mab F598 |
| Antibody type and class | IgG1 |
| Assay System | Enzyme-linked immunosorbent assays, complement deposition, immunofluorescence and opsonophagocytic assays |
| Cross-reactivity | This Mab was specfic to S. aureus and was found to be nonreactive against alginate from Pseudomonas aeruginosa strain PAO 581, the P. aeruginosa LPS O antigens from serogroups 02 and 06, and the PS/A antigen of Bacteroides fragilis |
| Proposed epitopes | This Mab bound best to nonacetylated or backbone epitopes on PNAG |
| IEDB Epitope | N/A |
| Proposed Utility | This Mab had superior complement deposition and opsonophagocytic activity. This Mab also had optimal protective efficacy. This Mab could be immunotherapeutic agent for preventing or treating staphylococcal infections. |
| Curator ID | AA + AS |
| Date of Curation | 24-04-2011
|
| References | 16622211 |